Bionime Corp represents a range of values and a corporate philosophy focused on innovation, quality, and customer satisfaction. The company is dedicated to developing advanced medical devices and solutions to meet the needs of healthcare professionals and patients. With a commitment to accuracy, reliability, and user-friendly products, Bionime Corp aims to enhance the management of diabetes and improve the overall quality of life for individuals living with the condition. By continuously investing in research and development, Bionime Corp strives to provide cutting-edge technology and personalized healthcare solutions to contribute to the well-being of its customers.

Bionime Corp is primarily present in several countries and regions. The company has a significant presence in Taiwan, where it is headquartered. Additionally, Bionime Corp operates in various Asian markets, including China, Hong Kong, Japan, and Southeast Asian countries. It has expanded its reach to the United States, Canada, and several European countries as well. Bionime Corp's global presence allows it to serve a wide range of customers and cater to different markets' demands.

Significant milestones achieved by Bionime Corp include the development of innovative medical devices and solutions, establishing a strong global presence, and receiving numerous certifications and awards. The company has successfully launched advanced products such as blood glucose monitoring systems and continuous glucose monitoring systems, which have improved the lives of individuals managing diabetes. Bionime Corp has expanded its market reach by establishing partnerships and distribution networks in various countries. Additionally, the company has earned recognition through certifications like ISO 13485 and FDA approvals for its quality management systems. These achievements highlight Bionime Corp's commitment to enhancing healthcare and creating impactful solutions for patients worldwide.

Bionime Corp is a renowned global medical technology company specializing in the development, manufacturing, and marketing of innovative healthcare products. Established in 2003, Bionime has made significant strides in the field of diabetes management. With a commitment to improving the lives of individuals living with diabetes, Bionime focuses on developing advanced blood glucose monitoring systems and related solutions. The company's expertise lies in creating user-friendly, accurate, and reliable products that empower patients to effectively manage their condition. With a strong emphasis on research and development, Bionime has emerged as a trusted brand in the healthcare industry, continuously striving for technological advancements and breakthroughs in diabetes care.

Bionime Corp faces competition from prominent players in the market such as Abbott Laboratories, Roche Holding AG, and Johnson & Johnson. These companies are also engaged in the development and manufacturing of medical devices, including glucose monitoring systems. However, Bionime Corp stands out with its innovative products and solutions, such as their blood glucose monitoring systems and diabetes management applications. With its focus on providing accurate and user-friendly products, Bionime Corp has carved a niche for itself in the market, distinguishing itself from its competitors through its commitment to high-quality healthcare solutions.

Bionime Corp primarily operates in the healthcare and medical equipment industries.

The business model of Bionime Corp is focused on developing and manufacturing advanced medical devices and solutions for diabetes management. They specialize in creating innovative blood glucose monitoring systems, including blood glucose meters, test strips, and other related products. Bionime Corp aims to provide accurate and reliable diabetes management tools to help individuals effectively monitor their blood sugar levels and make informed decisions about their health. With their commitment to technological advancements and quality products, Bionime Corp strives to improve the lives of people living with diabetes worldwide.

Bionime KGV ir 55,17.

Bionime KUV ir 1,91.

AlleAktien kvalitātes vērtējums Bionime ir 3/10.

gaidāmā Bionime apgrozījums ir 2,14 miljardi TWD.

gaidāmā Bionime peļņa ir 74,06 milj. TWD.

Bionime Corp is a global leader in diabetes management products and medical diagnostic devices. The company, headquartered in Taiwan with branches in Europe, North America, and Asia, focuses on developing innovative measuring devices and patient management systems to improve the health of diabetes patients.

Bionime izmaksā dividendes 2,00 TWD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Bionime vai uzņēmums nedod dividendes.

Bionime ISIN ir TW0004737002.

Bionime simbols ir 4737.TW.

Pēdējo 12 mēnešu laikā Bionime maksāja dividendes 2,10 TWD apmērā. Tas atbilst aptuveni 3,15 % dividendes ražībai. Nākamajos 12 mēnešos Bionime plāno maksāt dividendes 2,10 TWD apmērā.

Bionime pašreizējā dividendu rentabilitāte ir 3,15 %.

Bionime maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos augusts, augusts, augusts, augusts.

Bionime pēdējo 15 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 2,10 TWD. Tas atbilst dividendes ražībai 3,15 %.

Bionime tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Bionime apmērā 1,999 TWD, kas tika izmaksāta 23.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 29.07.2024..

Pēdējās dividendes izmaksa notika 23.08.2024..

Gadā 2023, Bionime izmaksāja 1,999 TWD dividendes.

Bionime dividendes tiek izmaksātas TWD.